Atsuko Mugitani

596 total citations
28 papers, 219 citations indexed

About

Atsuko Mugitani is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Atsuko Mugitani has authored 28 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 9 papers in Oncology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Atsuko Mugitani's work include Acute Myeloid Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (5 papers). Atsuko Mugitani is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (5 papers). Atsuko Mugitani collaborates with scholars based in Japan. Atsuko Mugitani's co-authors include Masayuki Hino, Takahisa Yamane, Kensuke Ohta, Yasutaka Aoyama, Kaori Makita, Masahiro Manabe, Joji Nagasaki, Erina Sakamoto, Hideo Koh and Hirohisa Nakamae and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Atsuko Mugitani

26 papers receiving 212 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Atsuko Mugitani Japan 8 94 78 54 39 37 28 219
H. G. Derigs Germany 6 103 1.1× 133 1.7× 53 1.0× 38 1.0× 35 0.9× 11 264
Tsuneaki Hirakawa Japan 6 98 1.0× 83 1.1× 71 1.3× 52 1.3× 30 0.8× 20 248
Dipenkumar Modi United States 10 132 1.4× 129 1.7× 64 1.2× 31 0.8× 27 0.7× 61 272
Victoria R. Alegria United States 8 105 1.1× 82 1.1× 60 1.1× 73 1.9× 77 2.1× 38 249
Po‐Shen Ko Taiwan 10 87 0.9× 80 1.0× 73 1.4× 46 1.2× 44 1.2× 37 260
Ambra Paolini Italy 9 77 0.8× 35 0.4× 23 0.4× 44 1.1× 42 1.1× 16 199
Shinichiro Machida Japan 8 151 1.6× 74 0.9× 36 0.7× 34 0.9× 60 1.6× 39 258
Kiyomi Morita United States 10 140 1.5× 76 1.0× 39 0.7× 54 1.4× 55 1.5× 31 254
Caroline Jacquy Belgium 7 91 1.0× 96 1.2× 52 1.0× 21 0.5× 20 0.5× 12 229
Simona Sammassimo Italy 7 70 0.7× 79 1.0× 55 1.0× 27 0.7× 31 0.8× 26 158

Countries citing papers authored by Atsuko Mugitani

Since Specialization
Citations

This map shows the geographic impact of Atsuko Mugitani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atsuko Mugitani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atsuko Mugitani more than expected).

Fields of papers citing papers by Atsuko Mugitani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atsuko Mugitani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atsuko Mugitani. The network helps show where Atsuko Mugitani may publish in the future.

Co-authorship network of co-authors of Atsuko Mugitani

This figure shows the co-authorship network connecting the top 25 collaborators of Atsuko Mugitani. A scholar is included among the top collaborators of Atsuko Mugitani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atsuko Mugitani. Atsuko Mugitani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harada, Naonori, et al.. (2024). Infectious mononucleosis due to Epstein-Barr virus reactivation in an immunocompromised 60-year-old patient with COVID-19. Journal of Infection and Chemotherapy. 30(11). 1182–1185.
2.
Mukai, Daiki, et al.. (2023). MRI findings of nelarabine‐related rhabdomyolysis in a patient with refractory T‐cell acute lymphoblastic leukemia. SHILAP Revista de lepidopterología. 4(3). 865–866. 1 indexed citations
3.
Harada, Naonori, et al.. (2023). Sudden-onset gallbladder rupture due to Ceftriaxone-associated pseudolithiasis in a patient with acquired hemophilia A. Journal of Infection and Chemotherapy. 29(8). 796–799.
4.
Hashimoto, Yoshinori, Hirohisa Nakamae, Takayuki Tanaka, et al.. (2018). Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. European Journal Of Haematology. 101(4). 508–513. 9 indexed citations
5.
Aoyama, Yasutaka, Joji Nagasaki, Hiroshi Harada, et al.. (2017). Pulmonary Involvement of Acute Myeloid Leukemia Mimicking Transfusion-related Acute Lung Injury. Internal Medicine. 56(18). 2493–2496. 1 indexed citations
6.
7.
Nagasaki, Joji, et al.. (2016). Reversible dasatinib-related pulmonary arterial hypertension in a CML patient.. PubMed. 57(5). 618–23. 1 indexed citations
8.
Manabe, Masahiro, Takafumi Nishii, Naonori Harada, et al.. (2013). Chronic myelogenous leukemia after postoperative adjuvant S-1 therapy for rectal cancer: a case report.. PubMed. 3(4). 286–9. 2 indexed citations
9.
Manabe, Masahiro, Hirofumi Nakano, Naonori Harada, et al.. (2012). Derivative (5;19)(p10;q10): A rare but recurrent whole‐arm translocation in acute myeloid leukemia. Asia-Pacific Journal of Clinical Oncology. 10(2). e122–6. 2 indexed citations
10.
Hosen, Naoki, Atsuko Mugitani, Yasutaka Aoyama, et al.. (2011). CD48 as a novel molecular target for antibody therapy in multiple myeloma. British Journal of Haematology. 156(2). 213–224. 37 indexed citations
11.
Terada, Yoshiki, Hirohisa Nakamae, Erina Sakamoto, et al.. (2009). Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. Journal of Experimental & Clinical Cancer Research. 28(1). 116–116. 49 indexed citations
12.
Ishii, Kazuyoshi�, Fumiaki Urase, Masahiro Manabe, et al.. (2009). VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience. Archives of Gerontology and Geriatrics. 51(2). 209–215. 7 indexed citations
13.
Terada, Yoshiki, Hirohisa Nakamae, Erina Sakamoto, et al.. (2008). The Impact of Relative Dose Intensity of Rituximab-CHOP on Survival in Diffuse Large B-Cell Lymphoma Patients. Blood. 112(11). 4931–4931. 3 indexed citations
14.
15.
Tanaka, Hajime, et al.. (2007). Effectiveness of Reporting System for Carbapenem Antibiotics in Restricting Their Use. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 33(10). 877–882. 2 indexed citations
16.
Aoyama, Yasutaka, Atsuko Mugitani, Takahisa Yamane, et al.. (2006). [Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange].. PubMed. 47(12). 1528–32. 2 indexed citations
17.
Ishii, Kazuyoshi�, Y. Yamamoto, Hitoshi Kitayama, et al.. (2005). [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].. PubMed. 32(1). 39–44. 1 indexed citations
18.
Hirose, Asao, Takahisa Yamane, Y. Nakajima, et al.. (2005). [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].. PubMed. 32(13). 2059–64. 1 indexed citations
19.
Makita, Kaori, et al.. (2003). Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplantation. 33(6). 661–665. 40 indexed citations
20.
Mugitani, Atsuko, et al.. (2000). Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.. PubMed. 19(4C). 3393–7. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. G. Derigs Breakdown of academic impact, for papers by Tsuneaki Hirakawa Breakdown of academic impact, for papers by Dipenkumar Modi Breakdown of academic impact, for papers by Victoria R. Alegria Breakdown of academic impact, for papers by Po‐Shen Ko Breakdown of academic impact, for papers by Ambra Paolini Breakdown of academic impact, for papers by Shinichiro Machida Breakdown of academic impact, for papers by Kiyomi Morita Breakdown of academic impact, for papers by Caroline Jacquy Breakdown of academic impact, for papers by Simona Sammassimo
Rankless by CCL
2026